Ramiro Guillen
Child & Adolescent Psychiatry · Scottsdale, AZNPI 1104993500
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,660 of the $30,810 with a category attached, or 70.3%. 19 manufacturers reported payments, led by Johnson & Johnson at 48.9% of the total. Reporting peaked in 2019 at $25,143 and has fallen 99.2% since, to $205 in 2025. Among child & adolescent psychiatry clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 255 payments — averaging $120.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$15K
- Ironshore Pharmaceuticals Inc.$10K
- Supernus Pharmaceuticals, Inc.$3K
- Sunovion Pharmaceuticals Inc.$685
- Otsuka America Pharmaceutical, Inc.$519
- Corium, LLC$438
- plus $1K from 13 others
What the payments were for
- Speaking & faculty fees$21,66070%
- Travel & lodging$4,12213%
- Food & beverage$5,01516%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 50 | $15,059 |
| Ironshore Pharmaceuticals Inc. | 34 | $9,793 |
| Supernus Pharmaceuticals, Inc. | 9 | $2,864 |
| Sunovion Pharmaceuticals Inc. | 54 | $685 |
| Otsuka America Pharmaceutical, Inc. | 25 | $519 |
| Corium, LLC | 12 | $438 |
| Alkermes, Inc. | 14 | $321 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $316 |
| AbbVie | 5 | $164 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $140 |
| Neurocrine Biosciences, Inc. | 7 | $139 |
| Shire North American Group Inc | 7 | $113 |
| Brainsway USA Inc | 2 | $89 |
| Teva Pharmaceuticals USA, Inc. | 2 | $48 |
| Vanda Pharmaceuticals Inc. | 2 | $45 |
| Adlon Therapeutics L.p. | 2 | $27 |
| Vertical Pharmaceuticals, LLC | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
| Neos Therapeutics, LP | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$14,210
- Jornay PM 20mg capsules (Bottle of 100)$9,175
- Azstarys$230
- VRAYLAR$123
How this compares
$30,810 in reported general payments places this provider in the 95th percentile of 80 child & adolescent psychiatry providers in Arizona.
See all child & adolescent psychiatry providers in Arizona →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lisdexamfetamine Dimesylate | 12 | $2,266 |
| Bupropion XlBupropion Hcl | 69 | $1,511 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 45 | $1,383 |
| Atomoxetine Hcl | 12 | $843 |
| Lamotrigine | 31 | $718 |
| Fluoxetine Hcl | 20 | $645 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 17 | $567 |
| Trazodone Hcl | 27 | $527 |
| Lorazepam | 36 | $426 |
| Escitalopram Oxalate | 31 | $392 |
| Duloxetine Hcl | 24 | $380 |
| Clonazepam | 73 | $371 |
| Lurasidone Hcl | 13 | $339 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 14 | $297 |
| Ziprasidone Hcl | 11 | $239 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Scottsdale
- Linda KalivasScottsdale$13K
- Palpu HazelScottsdale$13K
- Kenneth ZwierScottsdale$7K
- Roya KarbakhshScottsdale$6K
- Fariba PfitznerScottsdale$5K
- Shaili PatelScottsdale$3K
- Marilyn Pupo GuillenScottsdale$2K
- Lilia Romero-BoschScottsdale$1K
- Patricia Tagle-LevyScottsdale$732
- Sandeep KaurScottsdale$626
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.